The present study deals with the development of hydroxyapatite (HAp)-ciprofloxacin bone-implants using the »Quality by design« approach. The effect of various synthesis parameters like drug amount added in the process, stirring speed and addition rate of orthophosphoric acid in the synthesis on drug concentration in the HAp--ciprofloxacin system synthesized by the precipitation technique using 2 3 factorial design was analyzed. Optimization methodology utillizing the first-order polynomial equation was used to search for optimal drug concentration in the HAp-ciprofloxacin implant system. The observed responses coincided well with the predicted values from the optimization technique. New implants were manufactured using various HAp-ciprofloxacin composites and 1.5 % (m/V) guar gum as a binder. Characterization of the delivery system was done by XRPD, FTIR spectroscopy and SEM. Even at highest drug concentration (76.6 ± 0.5 %, m/m), ciprofloxacin was present in noncrystalline state. The in vitro ciprofloxacin release from various bone-implants was sustained for several weeks and the drug release pattern correlated well with the Korsmeyer-Peppas model.
Keywords: hydroxyapatite, ciprofloxacin, bone-implant, »Quality by design«, osteomyelitis patibility and bone-bonding property, HAp has been used as a safe matrix in the bone drug delivery (4, 5) . It also offers high binding affinity for a variety of pharmacological substances such as antibiotics, hormones, steroids, etc. (6) (7) (8) . This has opened the potential of using HAp to deliver various pharmacological substances in many clinical applications.
Ciprofloxacin is a fluroquinolone derivative, widely used in osteomyelitis because of its favorable penetration and bactericidal effect on all the probable osteomyelitis pathogens (9) . An investigation of the HAp-ciprofloxacin system was performed by Pham et al. based on the precipitation and spray drying techniques (10) . But, the drug release kinetics from these delivery systems (sustained release of ciprofloxacin for a few days only) were not as satisfactory as expected from an implantable system for bone delivery. The effectiveness of an antibiotic therapy to treat bone infections involves irrigating the infected site by the therapeutic level of antibiotic concentration for several weeks (11) . In our initial investigation, we found high ciprofloxacin concentration (up to 76.6 ± 0.5 %, m/m) in an HAp-based system synthesized by the precipitation technique and by varying synthesis parameters such as drug amount added and addition rate of orthophosphoric acid (10) . In this case, the addition rate of orthophosphoric acid was slower (1 mL min -1 and 0.5 mL min -1 ) in comparison with earlier literature reports on the precipitation technique (9) , and thus we have formulated HAp-ciprofloxacin minipellets for bone-implantable delivery by compressing synthesized HAp-ciprofloxacin powders. The in vitro ciprofloxacin release from these minipellets was slow and sustained for several weeks. In the present investigation, we have attempted to increase drug concentration in implants, which will reduce the total mass and size of implants. This may work like small surgery and decreases hospitalization period. Therefore, in the present investigation, we have attempted to analyze the effect of various synthesis parameters such as the drug amount added in the process, stirring speed and addition rate of orthophosphoric acid in the synthesis on drug concentration in the HAp-system. The precipitation technique using 2 3 factorial design was used to develop HAp-ciprofloxacin bone-implants »Quality by design (QbD)«. QbD encompasses designing and developing formulations and manufacturing processes that ensure ensure predefined product specifications. An important part of QbD is to understand how process and formulation parameters affect the product quality and subsequent optimization of these parameters with respect to final specifications (12) . Also, we have used guar gum, a natural biodegradable material, as a binder to manufacture new HAp-ciprofloxacin bone-implants, which was not common by used in previous investigations (9) (10) (11) .
EXPERIMENTAL

Materials
Ciprofloxacin hydrochloride was a generous gift from Dr. Reddy's Laboratories (India). Calcium hydroxide (Qualigens Fine Chemicals, India), orthophosphoric acid (Qualigens Fine Chemicals, India) and guar gum (HiMedia Laboratories, India) were used. All other chemicals were of analytical grade.
Methods
Experimental design. -A three-factor, two-level factorial design (2 3 ) was employed for optimization, with the drug amount added in the process (X 1 ), stirring speed (X 2 ) and addition rate of orthophosphoric acid in the synthesis (X 3 ) as three prime selected independent variables. They were varied at two levels, low level (-1) and high level (+1). The percentage of drug in the HAp-system was used as a dependent variable. Design-Expert ® DX 7 software was used for the generation and evaluation of the statistical experimental design. The design matrix including the response (drug load) is shown in Table II .
Synthesis of HAp-ciprofloxacin composites. -The HAp-ciprofloxacin composites were prepared by the precipitation technique. In brief, 50 mL of aqueous suspension of 0.5 mol L -1 calcium hydroxide was prepared and vigorously stirred for 10 min. 50 mL of 0.3 mol L -1 orthophosphoric acid was slowly added into the calcium hydroxide suspension. Then, the drug was added and pH (10.5) was carefully adjusted with 1 mol L -1 ammonium hydroxide. The suspension was well stirred using a magnetic stirrer for 30 min and aged overnight at room temperature. The precipitate was subjected to vacuum filtering using a Büchner funnel, repeatedly washed with deionized water and filtered again. The precipitates was dried at room temperature for 48 hours. Dried lumps of composites were ground using clean mortars and pestles.
Determination of drug concentration and drug loading. -Filtrates of the suspensions of HAp-ciprofloxacin composites, which were obtained after washing with deionized water, were taken and analyzed to determine the drug loading and drug incorporation efficiencies. Absorbance values were measured from filtrate dilutions of different formulations at 274 nm using a UV-VIS spectrophotometer (Thermo Spectronic UV-1, USA). Drug concentration and drug loading were calculated.
Manufacturing HAp-ciprofloxacin bone-implants. -HAp-ciprofloxacin composites (2 g) were mixed with 2.5 mL of 1.5 % (m/V) aqueous solution of guar gum to make a smooth paste and were then poured into 2.5-mm diameter cylindrical moulds using an extruder syringe. After hardening, cylindrical rods (diameter 2.5 mm) were removed from moulds and dried at room temperature for 24 hours. The cylindrical rods were cut into pellet-sized implants. The geometry of the implants was cylindrical with an average length of 2 mm and diameter of 2.5 mm.
Characterization of the HAp-ciprofloxacin delivery system
X-ray powder diffraction (XRPD). -Samples were exposed to CuKa radiation (35 kV 30 mA) in a wide-angle X-ray diffractomter (SEIFERT X-Ray Diffractometer, XRD 3000 P, RICH SEIFERT & Co., Germany). The instrument was operated in the step-scan mode with increments of 0.050°2q. The angular range was 5 to 40°2q, and counts were accumulated for 1 second at each step.
Fourier transform infrared (FTIR) spectroscopy. -The samples were triturated to powder and analyzed in KBr pellets using a Perkin Elmer Spectrum RX I spectrometer (Perkin Elmer, USA).
Scanning electron microscopy (SEM). -
The samples were gold coated in an ion sputter (Hitachi E1010, Japan) and their microstructures were examined with a scanning electron microscope (Hitachi S3400, Japan).
In vitro release of ciprofloxacin from implants. -Samples containing 5 bone-implants of each formulation were placed in Falcon tubes containing 5 mL of pH 7.4 phosphate buffer saline (PBS) at 37 ± 0.5°C. Elution fluids were collected and the same volume of fresh buffer was replaced at regular intervals. Collected elution fluids were used for determination of antibiotic concentration at 271 nm.
Data analysis
The purpose for using a full factorial experimental design was to conduct a comprehensive study of the effect of process parameters and their interactions using a suitable statistical tool (Design-Expert ® DX 7 Software) by applying one-way ANOVA. Individual response parameters were evaluated using the F-test. Mathematical modeling was carried out to obtain a first-order polynomial equation depending on significant influences of the three factors (X 1 , X 2 and X 3 ) of the factorial design model using the following equation:
where Y is the dependent variable, while b 0 is the intercept, 6 and b 7 are regression coefficients; X 1 X 2 , X 2 X 3, X 1 X 3 and X 1 X 2 X 3 are interactions between the main effects.
Release kinetics modelling
The in-vitro ciprofloxacin release data from implants were evaluated kinetically using various mathematical models, such as zero-order, first-order, Higuchi, Hixon-Crowell and Korsmeyer-Peppas model (9, (13) (14) :
for zero-order kinetics: F = k o t, where F represents the fraction of drug released in time t, and k o is the apparent release rate constant or zero-order release constant; for first-order kinetics: ln(1-F) = -k 1 t, where F represents the fraction of drug released in time t, and k 1 is the first-order release constant; for Higuchi model: 
where F = 1 -(W t /W o ) and F represents the drug dissolved fraction at time t, and k E is the release constant). for Korsmeyer-Peppas model: F = k P t n , where F represents the drug fraction released in time t, k P is the rate constant and n is the diffusional exponent; this indicates the drug release mechanism.
RESULTS AND DISCUSSION
Factorial design
Hydroxyapatite-ciprofloxacin composites were prepared by the precipitation technique according to the 2 3 factorial design. For the 2 3 factorial design, a total of 8 experimental formulations were prepared for 3 factors, the drug amount added in the process, stirring speed and addition rate of orthophosphoric acid in the synthesis, at 2 levels (high and low). Values of the drug concentration data in the 2 3 factorial design (Table I) were fitted to a first-order polynomial model. Our model equation became:
The results of ANOVA, as shown in 
F-HCip/1 1 (+1) 1000 (+1) 100 (+1) 11.9 ± 0.7 maximizing the ciprofloxacin concentration in the HAp-system was to set the goal to locate the optimum settings of independent variables in the new formulations by QbD, and these new formulations were formulated using the optimum settings of independent variables (Table III) . QbD stresses the need to thoroughly understand the critical process parameters with the aim of achieving successful product development with predefined quality attributes (15) . Critical quality attributes are the properties that need to be controlled as they affect either patent safety or efficacy (16) . Optimized HAp-ciprofloxacin composites were evaluated for ciprofloxacin concentration. showed high concentration of ciprofloxacin of 75.2 ± 0.6 and 76.6 ± 0.5 % m/m with high drug loading efficiency of 85.6 ± 0.1 % m/m and 87.4 ± 0.2 % m/m, respectively (Tables  III and Table IV) .
XRPD
X-ray powder diffraction profiles of standard ciprofloxacin hydrochloride, HAp-ciprofloxacin composites and HAp blank powders are shown in Fig. 1 . XRPD profiles of HAp-ciprofloxacin composites did not show any major differences in characteristic peaks for HAp from that of HAp blank powder, indicating that the drug (here ciprofloxacin) might be present in a noncrystalline form or in solid solution in the HAp-system. Again, it clearly appeared that the XRPD pattern of standard ciprofloxacin hydrochloride showed significantly different diffraction features them that of HAp-ciprofloxacin composites and these differences might be due to presence of polycrystalline ciprofloxacin in the standard ciprofloxacin hydrochloride samples.
FTIR
Fourier transform infrared spectra of HAp blank powders, guar gum, standard ciprofloxacin hydrochloride, HAp-ciprofloxacin composites, and HAp-ciprofloxacin bone--implants are presented in Fig. 2 . Synthesized HAp blank powder and standard ciprofloxacin hydrochloride samples were used for comparison. The FTIR spectrum of synthesized HAp blank powder showed the characteristic peaks, namely PO 4 narrow peak at 963 cm -1 , the PO 4 peak at 1039 cm -1 , PO 4 peaks at 604 and 564 cm -1 , and the OH peak at 668 cm -1 , as expected (17) . Incorporation of ciprofloxacin into the HAp-system led to emergence of a characteristic peak (1625 cm -1 for C=O in ciprofloxacin) (18) . In the FTIR spectra of HAp-ciprofloxacin composites and HAp-ciprofloxacin bone-implants, the charac- 
SEM
Scanning electron microscopy images of HAp blank powders are presented in Fig.  3 . The images were present as rough, granular or dense aggregates. The particles showed different shapes, such as short and long columns, thick plates and needle. The SEM photographs of synthesized powders suggest the typical apatite appearance (19) . The microstructure of HAp blank powders synthesized using 100 mL min - orthophosphoric acid was comparatively dense; the particles were of different shapes (short and long columns, thick and needle-like plates). On the other hand, 0.5 mL min -1 adition rate of orthophosphoric acid resulted in relatively small particles spherical in shape with rough surfaces. The SEM photograph of HAp-ciprofloxacin composites synthesized using 0.5 mL min -1 of orthophosphoric acid addition rate (F-HCip/11) was found to be comparatively similar to that of HAp blank powders synthesized using the same addition rate of orthophosphoric acid. The microstructure of both samples probably helped provide more surface area to adsorb drug molecules, which increased the drug concentration and loading into the HAp-system. Various HAp-ciprofloxacin bone-implants (2 mm´2.5 mm) were prepared using various synthesized HAp-ciprofloxacin composites and 1.5 % (m/V) guar gum as a binder. Thus formulated implants were evaluated for in vitro drug release in PBS (pH 7.4). The in vitro ciprofloxacin release in PBS (pH 7.4) from the bone-implants was followed for 10 ( Fig. 4) . All implants (except F-HCip/3 and F-HCip/7) exhibited sustained release of ciprofloxacin for several weeks. Formulations F-HCip/10 and F-HCip/11 showed more sustained drug release than the others. These two formulations were prepared using HAp-ciprofloxacin composites with comparatively higher drug concentration and drug loadings efficiency. This indicates that the release rate of ciprofloxacin from these 33 A. Kumar Nayak et al.: Development of hydroxyapatite-ciprofloxacin bone-implants using »Quality by design«, Acta Pharm. 61 (2011) 25-36. Fig. 3 . SEM images of HAp blank powders synthesized using the addition rate of orthophosphoric acid: a) 100 mL min -1 , b) 0.5 mL min -1 and c) HAp-ciprofloxacin composite using the addition rate of orthosphoric acid of 0.5 mL min -1 (F-HCip/11). implants depended on the amount of drug concentration and drug load, as expected. Thus, the pattern of ciprofloxacin release from highly loaded HAp-ciprofloxacin bone--implants may enable clinicians to achieve and maintain a therapeutic drug concentration in the infected bone tissue area for a long period of time.
In order to predict and correlate the release behavior of ciprofloxacin from different implants, it is necessary to fit the release data into a suitable mathematical model. The results of curve fitting of in vitro data for various implants prepared from optimized HAp-ciprofloxacin composites into different mathematical models (9, (13) (14) are given in Table V . The drug release pattern of implants investigated in this research correlated well the Korsmeyer-Peppas model over a period of 21 days. Korsmeyer-Peppas model was employed in the in vitro drug release behavior analysis of various pharmaceutical formulations to distinguish between two competing release mechanisms, a Fickian (non--steady) diffusional release when n £ 0.45 and a case-II transport (zero-order kinetics) when n ³ 0 (20) . It would appear that the value of n (Korsmeyer-Peppas model) for three optimized formulations was lower than 0.45. We are inclined to believe that the mechanism of ciprofloxacin release from implants followed Fickian diffusion. Thus, the release of ciprofloxacin from these HAp implants was mostly diffusion based; relaxational release was not predominant.
CONCLUSIONS
In conclusion, the proposed methodology may enable the development of new HAp-ciprofloxacin bone-implants for local antibiotic therapy in osteomyelitis, offering several advantages. Prolonged release of an antibiotic from these implants at the infected site may achieve elevated local antibiotic concentration, while minimizing the risk of systemic toxicity. The high antibiotic concentration in implants would help reduce the 
